MedTrace Logo

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

NCT03281122 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2021-02-25

No results posted yet for this study

Summary

The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction

Conditions

Interventions

DRUG

Placebo

Specified dose on specified days

DRUG

BMS-986224

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2019-04-17
Completion
2019-04-17
FDA Drug
Yes

Countries

  • Czechia
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03281122 on ClinicalTrials.gov